Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) EBT Margin (2016 - 2025)

Historic EBT Margin for Marker Therapeutics (MRKR) over the last 9 years, with Q3 2025 value amounting to 162.11%.

  • Marker Therapeutics' EBT Margin fell 422600.0% to 162.11% in Q3 2025 from the same period last year, while for Sep 2025 it was 846.98%, marking a year-over-year increase of 10016400.0%. This contributed to the annual value of 5340.68% for FY2024, which is 49165900.0% down from last year.
  • As of Q3 2025, Marker Therapeutics' EBT Margin stood at 162.11%, which was down 422600.0% from 479.92% recorded in Q2 2025.
  • Over the past 5 years, Marker Therapeutics' EBT Margin peaked at 91.5% during Q4 2024, and registered a low of 1273.6% during Q1 2025.
  • Moreover, its 4-year median value for EBT Margin was 385.86% (2022), whereas its average is 467.01%.
  • Per our database at Business Quant, Marker Therapeutics' EBT Margin surged by 10377200bps in 2024 and then crashed by -10812600bps in 2025.
  • Quarter analysis of 4 years shows Marker Therapeutics' EBT Margin stood at 385.86% in 2022, then skyrocketed by 33bps to 259.0% in 2023, then skyrocketed by 135bps to 91.5% in 2024, then plummeted by -277bps to 162.11% in 2025.
  • Its EBT Margin stands at 162.11% for Q3 2025, versus 479.92% for Q2 2025 and 1273.6% for Q1 2025.